What is in Kybella?
KYBELLA™ (deoxycholic acid) injection is the first and only FDA-approved prescription nonsurgical treatment that is used in adults to improve the appearance and profile of moderate to severe fat below the chin (submental fat), also called, “double chin.” It is not known if KYBELLA™ is safe and effective in children less than 18 years of age. It is not known if KYBELLA™ is safe and effective for use outside of the submental area.
How Does Kybella Work?
The active ingredient in KYBELLA™ is deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into the fat beneath your chin, KYBELLA™ causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat.
You and your doctor will decide how many treatments you need. Once the desired aesthetic response is achieved with KYBELLA™, retreatment is not expected.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
Especially tell your healthcare provider if you take a medicine that prevents the clotting of your blood (antiplatelet or anticoagulant medicine).
You should not receive KYBELLA™ if you have an infection in the treatment area.
Is KYBELLA™ right for me?
Only you and your doctor can decide if KYBELLA™ is right for you. If you’re bothered by submental fullness, or double chin, ask your doctor about KYBELLA™.
What to expect with KYBELLA™
KYBELLA™ (deoxycholic acid) injection is the first and only FDA-approved nonsurgical treatment that contours and improves the appearance of submental fullness, sometimes referred to as “double chin”.
You and your doctor will design a customized treatment plan to help you improve your chin profile. Many patients experience visible contouring of their chin profile in two to four treatment sessions spaced at least one month apart. Up to 6 treatments may be administered.
KYBELLA™ has been the focus of a global clinical development program involving over 20 clinical studies with more than 2,600 patients worldwide, of which over 1,600 have been treated with KYBELLA™.